Lundbeck Q3 2019 Financial Results

Brexpiprazole PoC study in borderline personality disorder commenced Borderline Personality Disorder (BPD) * * * Pharmacotherapy focuses on key symptoms (aggression, irritability, depressed mood, behavioural dyscontrol and affective dysregulation, anxiety, psychoticism and hostility) Substantial unmet medical need - no drugs approved for BPD 1.5-2 million potential patients in the U.S. Study objective¹) To evaluate the efficacy and safety of 12-week brexpiprazole for the treatment of subjects diagnosed with BPD (n = 240) to provide a pharmacological treatment for BPD PoC study (phase II): * * Brexpiprazole (flexible dose 2-3mg) and placebo Primary endpoint: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) total score (Week 12) Secondary endpoints: Clinical Global Impression - Severity of Illness (CGI-S); Patient's Global Impression of Severity (PGI- S); Patient's Global Impression of Change (PGI-C) Scale; Clinical Global Impression - Improvement (CGI-I) Scale Headline results due in 2021 - Fast Track designation granted October 2019 1) Clinicaltrials.gov ID: NCT04100096 26 26 Lundbeck

View entire presentation